A clear lack of innovation in ophthalmic drug delivery Eye diseases are currently addressed only via 2 ways
Team
Jean GARREC Founder & CEO
Pharm D., MBA 15 years of business experience in the field of ophthalmic industry across different roles and functions (general management, subsidiaries establishment, global business development, market access, and government price negotiations).
Dr Jean CUINÉ Co-Founder & CTO
Ph.D, Pharm D. & MBA, 20 years international experience in drug development & drug delivery. Former Head of development (CMC, preclinical safety and regulatory) at Stallergenes Greer and NextPharma and R&D Program Director at Novartis
Dr Boris BIZET CMC project manager
Ph.D in Chemistry, Project Leader in CMC and expert in polymer synthesis and in chemical analytical methods development.
Dr Frédéric LALLEMAND Head of Pharmaceutical Development
Ph.D & Pharm D., expert in ophthalmic drug development. Former R&D manager in 2 ophthalmology. start-ups (Novagali, Horama) & in industry (Santen).
Board of directors
Director Dr Eric TEO, MD
Global Head of Safety at CSL-Behring
MBBS(Hons), MBA, FFPM, FRCP(Glasg), LLM, has broad experience across medical and regulatory affairs and pharmacovigilance in the global pharmaceutical industry for over two decades.
Director Jean-François BRUNET
Independent consulting CFO and controlling
M.Sc. & MBA (HEC), is an experienced CFO with an in-depth international exposure. He hold various CFO positions with CAC40 listed companies as well as with major global businesses.
Director Rick EISWIRTH
President and CEO at Alimera Sciences Inc.
Our investors & partners
Our academic partners
-
- Statista – Kantar Media 2021 UK study in 2020 on 24,024 respondents aged 15 years and older
- WHO publication, 2019 World Report on Vision
- Behar-Cohen et al. – SFO report 2015
- Global Data report: Glaucoma Global Drug Forecast and Market Analysis to 2026
- Okeke et al. – Ophthalmology Feb. 2009